RxDoctor Payments DataLook up a doctor →

Julie Burnham, DO

Neurology · Mount Clemens, MINPI 1336246966

Payments from drug & device makers

$836,307in general payments, 2019–2025

Across 2,392 payments — averaging $349.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • EMD Serono, Inc.$239K
  • Sanofi$185K
  • AstraZeneca$91K
  • Amgen$78K
  • AbbVie$57K
  • Genentech USA, Inc.$40K
  • plus $147K from 54 others

What the payments were for

  • Consulting fees$65,2468%
  • Speaking & faculty fees$649,18978%
  • Travel & lodging$68,4318%
  • Food & beverage$52,6776%
  • Education$7640%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
EMD Serono, Inc.477$239,103
Sanofi242$184,558
AstraZeneca(2 entities)140$90,919
Amgen(2 entities)240$77,752
AbbVie(2 entities)208$57,279
Genentech USA, Inc.64$39,735
Teva Pharmaceuticals USA, Inc.104$30,326
TG Therapeutics, Inc.35$23,864
Merck Kgaa6$18,287
E.r. Squibb & Sons, L.L.C.16$16,169
Bristol Myers Squibb64$15,668
Novartis113$7,531
Biohaven Pharmaceutical Holding Company Ltd.13$7,190
Pfizer45$5,381
Biohaven Pharmaceuticals, Inc.15$5,277
Johnson & Johnson(2 entities)10$2,829
UCB, Inc.122$2,252
Lundbeck LLC33$2,082
Biogen51$1,291
Sanofi-aventis U.S. LLC18$833
ANI Pharmaceuticals, Inc.10$740
Avanir Pharmaceuticals, Inc.45$725
Neurelis, Inc.27$561
Neurocrine Biosciences, Inc.22$464
Eisai Inc.24$445
Kyowa Kirin, Inc.20$417
Supernus Pharmaceuticals, Inc.15$351
Argenx US, Inc.16$340
Sunovion Pharmaceuticals Inc.17$333
Acorda Therapeutics, Inc15$284
Otsuka America Pharmaceutical, Inc.18$270
Acadia Pharmaceuticals Inc15$269
Amneal Pharmaceuticals LLC15$269
Upsher-smith Laboratories LLC10$228
Lilly USA, LLC12$226
Genentech, Inc.2$224
Adamas Pharmaceuticals, Inc.9$174
Sumitomo Pharma America, Inc.9$158
Corium, LLC7$144
Catalyst Pharmaceuticals, Inc.6$142
Banner Life Sciences, LLC3$105
Vanda Pharmaceuticals Inc.5$93
MDD US Operations, LLC5$87
GE HealthCare5$86
Greenwich Biosciences, Inc.4$84
Jazz Pharmaceuticals Inc.3$75
SK Life Science, Inc.3$65
Azurity Pharmaceuticals, Inc.3$50
Nevro Corp.2$50
Arbor Pharmaceuticals, Inc.3$44
Vertical Pharmaceuticals, LLC2$41
Assertio Therapeutics, Inc.2$34
Avion Pharmaceuticals2$33
Cycle Pharmaceuticals Inc2$32
Strongbridge US Inc.2$29
Otsuka Pharmaceutical Development & Commercialization, Inc.1$29
Alnylam Pharmaceuticals Inc.2$29
Mallinckrodt Hospital Products Inc.1$27
Tanabe Pharma America, Inc.1$26
OWP Pharmaceuticals, Inc.1$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$836,307 in reported general payments places this provider in the 95th percentile of 652 neurology providers in Michigan.

See all neurology providers in Michigan

Medicare billing

Part B allowed, 2024
$101,415
Medicare patients
275
Services billed
5,196

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate72$351,193
Kesimpta PenOfatumumab27$242,631
Everolimus13$129,279
CopaxoneGlatiramer Acetate14$81,689
FingolimodFingolimod Hcl38$69,049
Aimovig AutoinjectorErenumab-Aooe72$64,835
Teriflunomide35$62,864
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5015$61,511
NuedextaDextromethorphan Hbr/Quinidine40$59,257
QuliptaAtogepant33$57,597
Nurtec OdtRimegepant Sulfate27$52,911
Dalfampridine ErDalfampridine87$36,189
Emgality PenGalcanezumab-Gnlm18$26,680
Glatiramer Acetate13$24,603
RexultiBrexpiprazole13$22,937

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$269$351,19372 claims
Teva Pharmaceuticals USA, Inc.Copaxone$30,326$81,68914 claims
AbbVieQulipta, Linzess$57,279$64,91545 claims
Avanir Pharmaceuticals, Inc.Nuedexta$725$59,25740 claims
PfizerNurtec Odt$5,381$52,91127 claims
Otsuka America Pharmaceutical, Inc.Rexulti$270$22,93713 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$269$3,85433 claims
Upsher-smith Laboratories LLCTopiramate$228$1,66787 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 652 neurology providers in Michigan.

Other neurology in Mount Clemens

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →